Go to Wolters Kluwer VitalLaw.comGo to Wolters Kluwer VitalLaw.com
VitalLaw®
  • Find answers to your questions
  • Log in to access your subscriptions
In depth. On point.
In depth. On point.
  • Home
  • Legal Directory
  • Home
  • Legal Directory
In depth. On point.
  • Articles
    • Articles
  • Law Firms
    • Law Firms
  • Organizations
    • Organizations
    • HEALTH CARE REIMBURSEMENT NEWS—Federal rule targets IDR process inefficiencies with new disclosure and communication mandates
    • ADMINISTRATION OF FDC ACT—FDA GUIDANCE NOTICES: Statistical approaches to establishing bioequivalence guidance issued
    • ADMINISTRATION OF MEDICARE/MEDICAID PROGRAMS—DAB DECISIONS: Hospice enrollment denied after it failed to demonstrate operational status
    • ADMINISTRATION OF MEDICARE/MEDICAID PROGRAMS—DAB DECISIONS: Medicare enrollment effective date set to approved application receipt, not prior rejected filings
    • Dietary Supplements—D.D.C.: Manufacturer’s cost-of-compliance calculation violated non-aggregation principle
    • FALSE CLAIMS ACT—SETTLEMENT AGREEMENTS: Oglethorpe Inc. and executives agree to pay $32 million to resolve False Claims Act liability over Medicare overpayment retention
    • MEDICAL DEVICES—FDA GUIDANCE NOTICES: Content of human factors information in medical device marketing submissions guidance issued
    • REGULATION TRACKER—Information on pending or recently adopted regulations and regulation amendments
    • STRATEGIC PERSPECTIVES—Mail access to mifepristone continues for now but faces more potential obstacles
    • WORTH NOTING—Other Health Law litigation and regulatory developments
  • Articles
    • Articles
  • Law Firms
    • Law Firms
  • Organizations
    • Organizations

    Health Law Daily Wrap Up, STRATEGIC PERSPECTIVES—Mail access to mifepristone continues for now but faces more potential obstacles, (Jun 1, 2026)

    Organizations Mentioned:Danco Laboratories, L.L.C. | GenBioPro, Inc.

    By Sheila Lynch-Afryl, J.D., M.A.

    In addition to the pending cases, the FDA is undertaking a “science-based safety review” of the mifepristone REMS.

    After the Fifth Circuit blocked the dispensing of mifepristone by mail in May—prohibiting telehealth access even in ...

    By Sheila Lynch-Afryl, J.D., M.A.

    In addition to the pending cases, the FDA is undertaking a “science-based safety review” of the mifepristone REMS.

    After the Fifth Circuit blocked the dispensing of mifepristone by mail in May—prohibiting telehealth access even in states where abortion is legal—the U.S. Supreme Court stayed the order pending appeal. While mifepristone access remains unchanged for now, impending challenges to abortion pill access remain. On addressing the merits, for example, the Fifth Circuit could reach a similar conclusion, or the Northern District of Texas could restrict access in a different case challenging the FDA’s approval of the abortion pill. The FDA is also undertaking a “science-based safety review” of the mifepristone Risk Evaluation and Mitigation Strategy (REMS). No matter the source, it is likely that mifepristone access will again be restricted and that the issue will reach the Supreme Court.

    To read the entire article, click here.

    Companies: Danco Laboratories, L.L.C.; GenBioPro, Inc.

    MainStory: StrategicPerspectives DrugNews HouseNews SenateNews DrugBiologicNews FDCActNews GenericDrugNews LabelingNews PrescriptionDrugNews ReproductiveHealthCareNews SafetyNews SupremeCtNews

    © 2026 CCH Incorporated and its affiliates and licensors. All rights reserved.

    • Manage Cookie Preferences
    • Privacy Statement
    • Terms of Use